|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
HGF-induced phosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) pathway substrate p42/p44(erk) and phosphatidylinositol 3'-kinase (PI3K) pathway substrate Akt provided evidence for downstream activation of MEK and PI3K pathways in HNSCC.
|
11479233 |
2001 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition, p110alpha mRNA and protein expression in HNSCC may be regulated by these genomic aberrations as well as by epigenetic events.
|
12375266 |
2002 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The mRNA level of SCCRO and PIK3CA was significantly correlated to the gene copy number in nine HNSCC cell lines.
|
12796399 |
2003 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
|
15543611 |
2005 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified four missense mutations in the seven exons of PIK3CA from 38 HNSCC specimens (11%).
|
16533766 |
2006 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Concluding, PIK3CA could be an oncogene implicated in HNSCC development.
|
17549376 |
2007 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
One mechanism by which HPV-associated HNSCC might activate PI3K is increased expression of PIK3CA.
|
17848307 |
2007 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/AKT/mTOR pathway downstream to kinase receptors, such as EGFR, was found in 57-81% of head and neck squamous cell carcinoma (HNSCC), and was eventually associated with a loss of PTEN function. mTOR was shown to modulate cell proliferation, apoptosis, invasion, and angiogenesis.
|
17912526 |
2008 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PI3K-AKT pathway is a downstream signaling pathway that has recently been found to play an important role in head and neck squamous cell carcinoma (HNSCC).
|
22020886 |
2011 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Conditional activation of the PI3K/Akt pathway due to Pten deletion in the mouse head and neck epithelia gives rise to hyperproliferation, but only a few lesions progress to HNSCC.
|
22037217 |
2012 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Activation of the PI3K and epidermal growth factor receptor (EGFR) pathway is able to drive oncogenesis in multiple human cancers, including head and neck squamous cell carcinoma.
|
22065749 |
2011 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Overall, while somatic activating mutations within classical oncogenes including PIK3CA and RAS occur in HNSCC, they are relatively uncommon.
|
22833868 |
2012 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PIK3CA copy number status will serve as a marker of poor prognosis in patients with HNSCC.
|
22994622 |
2012 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using an integrated genomic analysis and validation methodology we confirm four molecular classes of HNSCC (basal, mesenchymal, atypical, and classical) consistent with signatures established for squamous carcinoma of the lung, including deregulation of the KEAP1/NFE2L2 oxidative stress pathway, differential utilization of the lineage markers SOX2 and TP63, and preference for the oncogenes PIK3CA and EGFR.
|
23451093 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The common oncogenes EGFR, RAS, CCND1, BRAF, and PIK3CA and tumor suppressor genes p53, CDKN2A and NOTCH are discussed for their associations with HNSCC.
|
23467835 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PI3K inhibitor PX-866 had anti-tumor efficacy in HNSCC models with PIK3CA alterations.
|
23607916 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Strikingly, all tumors with concurrent mutation of multiple PI3K pathway genes were advanced (stage IV), implicating concerted PI3K pathway aberrations in HNSCC progression.
|
23619167 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the present study, we determined the mutation status in members of the MAPK, PI3K-AKT and JAK-STAT pathways in HNSCC.
|
23670291 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified frequent PIK3CA mutations in patients with high-risk HNSCC confined predominantly to the oropharyngeal and sinonasal subsites; for the first time, mutation in AKT1 has been identified in HNSCC.
|
23852799 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The importance of PIK3CA alterations in squamous cell carcinoma of the head and neck (HNSCC) has raised interest in exploring agents targeting PI3K, the product of PIK3CA.
|
23873848 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
CTD_human |
In this study, we evaluated the in vitro and in vivo efficacy of rigosertib in both HPV(+) and HPV(-) HNSCCs, focusing on inhibition of the PI3K pathway.
|
23873848 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
As such, current research aimed at elucidating the interactions between PI3K/Akt/mTOR and other important signaling pathways which may drive resistance in HNSCC, such as p53, NF-κB, and MAPK, has become a prominent focus toward better understanding how to most effectively treat HNSCC.
|
24219320 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the HPV-negative patients (n=221), heavy alcohol consumption was significantly associated with SCNAs of oncogenes/oncosuppressors that were previously reported to occur frequently in HNSCCs: CDKN2A (q=0.005), FHIT (q=0.005), 11q13 region including CCND1, FADD and CTTN (q=0.005), ERBB2 (HER2) (q=0.009), 3q25-qter including CCNL1, TP63, DCUN1D1 and PIK3CA (q=0.014), and CSMD1 (q=0.019).But, TP53 mutations were not affected.
|
24278325 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pharmacologic profiling of eight anticancer agents in six HNSCC cell lines suggested that PIK3CA mutation may serve as a predictive biomarker for the drugs targeting the EGFR/PI3K pathway.
|
24425785 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have previously reported high incidence of PIK3CA somatic mutations in head and neck squamous cell carcinoma, particularly in pharyngeal cancers.
|
24511546 |
2014 |